EUROPEAN LEFT ATRIAL APPENDAGE CLOSURE CLUB

Dedicated to improving the safety and efficacy of LAAC and ultimately to improve patient outcomes.

Join us in our commitment to promoting best practices, fostering collaboration, and ultimately improving patient outcomes.

Together, we can shape the future of left atrial appendage closure.

Welcome to the European Left Atrial Appendage Closure Club (ELAACC), a dynamic community of experts committed to advancing the field of left atrial appendage closure (LAAC) and ensuring optimal patient outcomes.

The club is driven by core values of professionalism, integrity, and ambition.

Why ELAACC?

  • Rising Importance of LAAC: With the increasing use of LAAC devices as a crucial alternative to long-term oral anticoagulation therapy, the need for a standardized approach and best practices has never been more critical. ELAACC is here to fill that gap.

  • Technical Challenges: LAAC remains a complex procedure demanding expertise in various areas, from imaging to device selection. Collaboration among specialists in interventional cardiology, electrophysiology, and imaging is key to optimizing every aspect of the procedure.

  • Evolving Technology: The field of LAAC is rapidly evolving with new devices and technologies. ELAACC serves as a hub for collaboration with companies, scientific societies, and major cardiology meetings to drive trials, suggest device innovations, and promote good clinical practices.

  • Practice Standardization: Addressing the current variability in LAAC practices across centers and countries, ELAACC is dedicated to promoting standardization in device selection, imaging techniques, and antithrombotic management.

Future Initiatives:

  • Annual Meeting: ELAACC is organizing an annual meeting, bringing together experts for interactive discussions and debates. This platform aims to develop consensus documents on patient selections, procedural techniques, and follow-up care for LAAC.

  • Registry Establishment: ELAACC is establishing a registry of LAAC procedures in Europe, extending its reach to other countries. This dedicated database will monitor outcomes and identify areas for improvement.

  • Multicenter Studies: ELAACC promotes multicenter studies, including randomized trials, to investigate the long-term safety and efficacy of LAAC, filling gaps in evidence and advancing the field.

  • Collaboration for Guidelines: ELAACC collaborates with other professional organizations to develop joint guidelines and consensus documents, ensuring a unified and evidence-based approach to LAAC.

In summary, the ELAACC is not just a club, it's a driving force for positive change in LAAC.

Meet the Committee

  • Dr Adel Aminian

    CHU Charleroi, Belgium

  • Dr Sergio Berti

    Fondazione CNR Regione Toscana, Massa, Italy.

  • Dr Ignacio Cruz-González

    Hospital Universitario de Salamanca, IBSAL, CIBER-CV, Salamanca, Spain.

  • Dr Ole De Backer

    Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

  • Dr Xavier Freixa

    Institut Clinic Cardiovascular, Hospital Clínic, Barcelona, Spain.

  • Dr Philippe Garot

    Institut Cardiovasculaire Paris Sud (ICPS) Hôpital J. Cartier, Massy, France

  • Dr Jens Erik Nielsen-Kudsk

    Aarhus University Hospital, Aarhus, Denmark.

  • Dr Lorenz Räber

    Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

  • Dr Nina Wunderlich

    Asklepios Klinik Langen, Frankfurt, Germany

ELAACC 2024

This year’s meeting is gratefully sponsored by the following companies specialising in the field of LAAC.

Please contact us for more information on how to become a partner of the ELAACC 2024 meeting.

PLATINUM SPONSOR

  • Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. We’re committed to advancing cardiology through less invasive technologies that improve outcomes, deliver care to more patients, reduce costs, and help millions live healthier lives.

    FIND OUT MORE:

    https://bostonscientific.com

SILVER SPONSOR

  • At Abbott, we are leading the way for structural heart therapies and challenging current treatment options to change the course of patient care. Our comprehensive portfolio is designed to be as minimally invasive as possible and to treat a broad range of patients with structural heart diseases, from infants to elderly patients. We’ve set a new standard of care as we relentlessly focus on delivering better solutions to more patients.

    FIND OUT MORE:

    https://www.structuralheart.abbott/

BRONZE SPONSOR

  • Established in 1999, LifeTech Scientific Corporation (Stock Code: 1302.HK) is committed to the R&D, manufacture, and sales of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases. Providing patients with innovative device solutions in the treatment of structural heart diseases, peripheral vascular diseases, and bradycardia, the company also expands its business scope in respiratory interventional business, neurointerventional business and interventional oncology business in the world marketplace. Over 1,900 high-quality patents have been filed of the company, and its sales network has penetrated more than 100 countries and regions around the world.

    FIND OUT MORE:

    https://www.lifetechmed.com/en

PARTICIPANT SPONSOR

  • With GE HealthCare Cardiology Solutions, you can increase collaboration, automate workflows and enable deeper insights. We're devoted to empowering heart care teams with integrated AI-powered solutions that optimize workflows, unlock efficiency and drive better patient outcomes.

    FIND OUT MORE:

    https://www.gehealthcare.com/products/ultrasound/vivid